994 resultados para ATORVASTATIN 80 MG


Relevância:

80.00% 80.00%

Publicador:

Resumo:

Leguminosas arbóreas têm sido muito utilizadas em programas de recuperação de áreas degradadas, dada a adaptação e crescimento em condições adversas e que se revertem em melhoria das condições físicas, químicas e biológicas do substrato. Esse estudo objetivou avaliar a fertilidade e o teor de C orgânico da camada superficial de uma área de empréstimo recuperada com duas leguminosas e lodo de esgoto, no Rio de Janeiro. O delineamento experimental foi o de blocos ao acaso, sendo os tratamentos a combinação de duas espécies de leguminosas (Sabiá, Mimosa caesalpiniifolia e Maricá, Mimosa bimucronata) e cinco doses de lodo de esgoto (0; 2,85; 5,70; 11,4 e 22,80 Mg ha-1). Após seis anos de crescimento amostras compostas foram avaliadas quanto ao pH, os teores de Ca, Mg e Al trocável, P e K disponíveis, acidez potencial e carbono orgânico.

Relevância:

40.00% 40.00%

Publicador:

Resumo:

OBJECTIVE To assess the effects of atorvastatin (ATORV) on renal function after bilateral ureteral obstruction (BUO), measuring inulin clearance and its effect on renal hemodynamic, filtration, and inflammatory response, as well as the expression of Aquaporin-2 (AQP2) in response to BUO and after the release of BUO. METHODS Adult Munich-Wistar male rats were subjected to BUO for 24 hours and monitored during the following 48 hours. Rats were divided into 5 groups: sham operated (n = 6); sham + ATORV (n = 6); BUO (n = 6); BUO + ATORV (10 mg/kg in drinking water started 2 days before BUO [n = 5]; and BUO + ATORV (10 mg/kg in drinking water started on the day of the release of BUO [n = 5]). We measured blood pressure (BP, mm Hg); inulin clearance (glomerular filtration rate [GFR]; mL/min/100 g); and renal blood flow (RBF, mL/min, by transient-time flowmeter). Inflammatory response was evaluated by histologic analysis of the interstitial area. AQP2 expression was evaluated by electrophoresis and immunoblotting. RESULTS Renal function was preserved by ATORV treatment, even if initiated on the day of obstruction release, as expressed by GFR, measured by inulin clearance. Relative interstitial area was decreased in both BUO + ATORV groups. Urine osmolality was improved in the ATORV-treated groups. AQP2 protein expression decreased in BUO animals and was reverted by ATORV treatment. CONCLUSION ATORV administration significantly prevented and restored impairment in GFR and renal vascular resistance. Furthermore, ATORV also improved urinary concentration by reversing the BUO-induced downregulation of AQP2. These findings have significant clinical implication in treating obstructive nephropathy. UROLOGY 80: 485.e15-485.e20, 2012. (c) 2012 Elsevier Inc.

Relevância:

40.00% 40.00%

Publicador:

Resumo:

O presente estudo teve como proposta identificar a população idosa, com mais de oitenta anos, residente na área de abrangência do Programa de Saúde da Família 18, em Patos de Minas - MG. Essa identificação se caracterizou por avaliar o perfil de cada idoso inserido na área delimitada. Para a elaboração do trabalho optou-se, inicialmente, por fazer uma revisão de literatura nas bases de dados LILACS, BDENF, SciELO, bem como da análise de fichas "A" da Equipe de Saúde da Família. Foi feito um roteiro com os dados de importância que seriam coletados nessas fichas. Os agentes de saúde é que levantaram esses dados. Cada um fez a análise das fichas A de sua microárea. A pesquisa evidenciou que o perfil dos idosos da área recortada não foge da tendência nacional, cujas características estão expressas no aumento da expectativa de vida, com destaque para o fato do percentual de mulheres idosas ser maior do que o dos homens. Quanto a alfabetização apresenta um grande percentual de analfabetos. A renda advém, majoritariamente, do beneficio previdenciário. Constatou-se também que existe um percentual muito grande de pessoas idosas que vivem sozinhas, ou na companhia do cônjuge, que também é idoso. No quesito saúde, os idosos entrevistados relataram poucas internações, sinalizando a predominância de doenças crônicas não transmissíveis, cujo tratamento requer uso continuado dos mesmos medicamentos, atestando a frequência das mesmas doenças. Os resultados encontrados permitirão à equipe de trabalho do Programa de Saúde da Família-18, de Patos de Minas, montar um programa de atendimento adequado ao perfil desses idosos, propiciando-lhes, assim, a melhor qualidade vida possível.

Relevância:

30.00% 30.00%

Publicador:

Resumo:

Fifteen strongly oscillating angular distributions of the elastic scattering of (12)C + (24)Mg at energies around the Coulomb barrier (E(c.m). = 10.67-16.00 MeV) are reproduced by adding five Breit-Wigner resonance terms to the l = 2, 4, 6, 7, and 8 elastic S matrix. The nonresonant, background elastic scattering S matrix S(l)(0) is calculated using the Sao Paulo potential. The J = 2, 4, 6, 7, and 8 (h) over bar molecular resonances fit well into a rotational molecular band, together with other higher lying resonances observed in the (16)O + (20)Ne elastic scattering. We propose that the presently observed, largely deformed molecular band corresponds to the hyperdeformed band, which has been found previously in alpha-cluster calculations, as well as in a new Nilsson model calculation. Systematic study of its possible clusterizations predicts the preference of the (12)C + (24)Mg and (16)O + (20)Ne molecular structure, in accordance with our present results.

Relevância:

30.00% 30.00%

Publicador:

Resumo:

Postmenopausal Caucasian women aged less than 80 years (n = 99) with one or more atraumatic vertebral fracture and no hip fractures, were treated by cyclical administration of enteric coated sodium fluoride (NaF) or no NaF for 27 months, with precautions to prevent excessive stimulation of bone turnover. In the first study 65 women, unexposed to estrogen (-E study), age 70.8 +/- 0.8 years (mean SEM) were all treated with calcium (Ca) 1.0-1.2 g daily and ergocalciferol (D) 0.25 mg per 25 kg once weekly and were randomly assigned to cyclical NaF (6 months on. 3 months off, initial dose 60 mg/day; group F CaD, n = 34) or no NaF (group CaD, n = 3 1). In the second study 34 patients. age 65.5 +/- 1.2 years, on hormone replacement therapy (E) at baseline, had this standardized, and were all treated with Ca and D and similarly randomized (FE CaD, n = 17, E CaD, n = 17) (+E study). The patients were stratified according to E status and subsequently assigned randomly to NaF. Seventy-five patients completed the trial. Both groups treated with NaF showed an increase in lumbar spinal density (by DXA) above baseline by 27 months: FE CaD + 16.2% and F CaD +9.3% (both p = 0.0001). In neither group CaD nor E CaD did lumbar spinal density increase. Peripheral bone loss occurred at most sites in the F CaD group at 27 months: tibia/fibula shaft -7.3% (p = 0.005); femoral shaft -7.1% (p = 0.004); distal forearm -4.0% (p = 0.004); total hip -4.1% (p = 0. 003); and femoral neck -3.5% (p = 0.006). No significant loss occurred in group FE CaD. Differences between the two NaF groups were greatest at the total hip at 27 months but were not significant [p < 0.05; in view of the multiple bone mineral density (BMD) sites, an alpha of 0.01 was employed to denote significance in BMD changes throughout this paper]. Using Cox's proportional hazards model, in the -E study there were significantly more patients with first fresh vertebral fractures in those treated with NaF than in those not so treated (RR = 24.2, p = 0.008, 95% CI 2.3-255). Patients developing first fresh fractures in the first 9 months were markedly different between groups: -23% of F CaD, 0 of CaD, 29% of FE CaD and 0 of E CaD. The incidence of incomplete (stress) fractures was similar in the two NaF-treated groups. Complete nonvertebral fractures did not occur in the two +E groups, there were no differences between groups F CaD and CaD. Baseline BMD (spine and femoral neck) was related to incident vertebral fractures in the control groups (no NaF), but not in the two NaF groups. Our results and a literature review indicate that fluoride salts. if used, should be at low dosage, with pretreatment and co-treatment with a bone resorption inhibitor.

Relevância:

30.00% 30.00%

Publicador:

Resumo:

Background Statins reduce the incidence of cardiovascular events in patients at high cardiovascular risk. However, a benefit of statins in such patients who are undergoing hemodialysis has not been proved. Methods We conducted an international, multicenter, randomized, double-blind, prospective trial involving 2776 patients, 50 to 80 years of age, who were undergoing maintenance hemodialysis. We randomly assigned patients to receive rosuvastatin, 10 mg daily, or placebo. The combined primary end point was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. Secondary end points included death from all causes and individual cardiac and vascular events. Results After 3 months, the mean reduction in low-density lipoprotein (LDL) cholesterol levels was 43% in patients receiving rosuvastatin, from a mean baseline level of 100 mg per deciliter (2.6 mmol per liter). During a median follow-up period of 3.8 years, 396 patients in the rosuvastatin group and 408 patients in the placebo group reached the primary end point (9.2 and 9.5 events per 100 patient-years, respectively; hazard ratio for the combined end point in the rosuvastatin group vs. the placebo group, 0.96; 95% confidence interval [CI], 0.84 to 1.11; P = 0.59). Rosuvastatin had no effect on individual components of the primary end point. There was also no significant effect on all-cause mortality (13.5 vs. 14.0 events per 100 patient-years; hazard ratio, 0.96; 95% CI, 0.86 to 1.07; P = 0.51). Conclusions In patients undergoing hemodialysis, the initiation of treatment with rosuvastatin lowered the LDL cholesterol level but had no significant effect on the composite primary end point of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. (ClinicalTrials.gov number, NCT00240331.)

Relevância:

30.00% 30.00%

Publicador:

Resumo:

Background: Risperidone (RSP) is a benzisoxazole antipsychotic agent used to treat schizophrenia and other psychiatric illnesses in adults and children (including those with autism). After oral administration, RSP is completely absorbed from the gastrointestinal tract and undergoes hydroxylation to yield 9-hydroxyrisperidone (9-OH-RSP), an active metabolite that has a pharmacologic profile and potency similar to RSP. Objectives: The aims of this study were to compare the relative bioavailability of a pharmaceutical-equivalent (test) formulation with a reference formulation of oral RSP 2 mg, both available commercially on the Brazilian pharmaceutical market, and to generate data regarding the oral bioavailability of the tested drug in healthy Brazilian volunteers. Methods: This single-dose, randomized-sequence, open-label, 2-period crossover study was conducted in healthy Brazilian volunteers from August to December 2008. Subjects were randomly assigned to receive the test formulation followed by the reference formulation or vice versa, with a 30-day washout period between doses. Study drugs were administered after a 12-hour overnight fast. For pharmacokinetic analysis, blood samples were drawn at 0 (baseline), 0.25, 0.5, 1, 1.5, 3, 5, 8, 12, 24, 48, 72, 96, and 120 hours after administration. Plasma concentrations of RSP and 9-OH-RSP were determined using LC-MS/MS. The test and reference formulations were to be considered bioequivalent if the 90% CIs for the geometric mean test/reference ratios were within a predetermined range of 80% to 125%, in accordance with the policies of the Brazilian Sanitary Surveillance Agency and the US Food and Drug Administration. Tolerability was determined using clinical assessments, monitoring of vital signs, analysis of laboratory test results, and subject interviews regarding adverse events. Results: A total of 22 subjects were enrolled (11 men, 11 women; mean [SD] age, 32 [12] years [range, 18-58 years]; weight, 70.4 [11.9] kg [range, 50-103 kg]; height, 1.67 [0.08] m [range, 1.56-1.80 m]; and body mass index, 25 [4] kg/m(2) [range, 18-29 kg/m(2)]). For RSP, mean (SD) C(max) values were 12.6 (2.7) and 16.0 (2.3) ng/mL for the test and reference formulations, respectively. For 9-OH-RSP, mean C(max) values were 17.8 (1.3) and 21.0 (1.7) ng/mL for the test and reference formulations. The 90% CIs for the mean test/reference ratios for RSP C(max), AUC(0-120), and AUC(0-infinity) were 74% to 82%, 75% to 85%, and 76% to 85%, respectively, and 83% to 87%, 75% to 79%, and 75% to 78% for 9-OH-RSP. The related adverse events (headache, low back pain, drowsiness, standing hypotension, local postvenipuncture ecchymoses, insomnia, nausea, and vomiting) were transient and mild. Conclusions: This single-dose study found that the test and reference formulations of oral RSP 2 mg did not meet the Brazilian and US regulatory criteria for bioequivalence in these fasting, healthy volunteers. The study formulations appeared to be well tolerated. (Clin Ther 2010;32:2106-2115) (C) 2010 Elsevier HS Journals, Inc.

Relevância:

30.00% 30.00%

Publicador:

Resumo:

Espécimes de Sarasinula marginata foram coletadas em hortas e jardins residenciais de Belo Horizonte, Minas Gerais. A suscetibilidade desta espécie de lesma ao Angiostrongylus costaricensis foi verificada em laboratório, utilizando-se 15 exemplares da geração F1. Foi demonstrada uma positividade de 80,0%

Relevância:

30.00% 30.00%

Publicador:

Resumo:

OBJECTIVE: Combined hyperlipidaemia is a common and highly atherogenic lipid phenotype with multiple lipoprotein abnormalities that are difficult to normalise with single-drug therapy. The ATOMIX multicentre, controlled clinical trial compared the efficacy and safety of atorvastatin and bezafibrate in patients with diet-resistant combined hyperlipidaemia. PATIENTS AND STUDY DESIGN: Following a 6-week placebo run-in period, 138 patients received atorvastatin 10mg or bezafibrate 400mg once daily in a randomised, double-blind, placebo-controlled trial. To meet predefined low-density lipoprotein-cholesterol (LDL-C) target levels, atorvastatin dosages were increased to 20mg or 40mg once daily after 8 and 16 weeks, respectively. RESULTS: After 52 weeks, atorvastatin achieved greater reductions in LDL-C than bezafibrate (percentage decrease 35 vs 5; p < 0.0001), while bezafibrate achieved greater reductions in triglyceride than atorvastatin (percentage decrease 33 vs 21; p < 0.05) and greater increases in high-density lipoprotein-cholesterol (HDL-C) [percentage increase 28 vs 17; p < 0.01 ]. Target LDL-C levels (according to global risk) were attained in 62% of atorvastatin recipients and 6% of bezafibrate recipients, and triglyceride levels <200 mg/dL were achieved in 52% and 60% of patients, respectively. In patients with normal baseline HDL-C, bezafibrate was superior to atorvastatin for raising HDL-C, while in those with baseline HDL-C <35 mg/dL, the two drugs raised HDL-C to a similar extent after adjustment for baseline values. Both drugs were well tolerated. CONCLUSION: The results show that atorvastatin has an overall better efficacy than bezafibrate in concomitantly reaching LDL-C and triglyceride target levels in combined hyperlipidaemia, thus supporting its use as monotherapy in patients with this lipid phenotype.

Relevância:

30.00% 30.00%

Publicador:

Resumo:

Um inquérito epidemiológico sobre teníase-cisticercose foi realizado em Lagamar- MG em 1992. Cadastradas 1109 casas com 3344 habitantes. O inquérito abrangeu 875 (86%) famílias e foi respondido por um informante que, em 80% dos casos, foi o pai. Na cidade havia 100 chiqueiros em 100 (11,4%) casas que albergavam 406 suínos, em condições extremamente precárias. Em 300 (34,2%) casas havia o antecedente de teníase em algum membro da família. O antecedente de convulsão foi relatado por 125 (14,2%) famílias. O início das convulsões na idade adulta foi caracterizado em 39 (3 7,8%) famílias e o antecedente de doenças mentais foi relatado em 53 (6%) casas. Os exames parasitológicos de fezes mostraram ovos de Taenia spp em 24 (1,3%) das 1850 amostras examinadas.

Relevância:

30.00% 30.00%

Publicador:

Resumo:

O estudo foi conduzido em uma bacia hidrográfica experimental de primeira ordem de aproximadamente 3,5 km2 localizada próximo ao km 16 da estrada secundária ZF-02, do km 60 da rodovia BR-174 que liga Manaus - Boa Vista. O principal objetivo foi quantificar o balanço dos nutrientes Ca+2, Mg+2 Na+, K+e NO3 através da entrada via precipitação e saída via deflúvio. As coletas de água e os cálculos do fluxo de nutrientes foram feitos em base mensal por um período de um ano. Observou-se que as concentrações iônicas apresentaram pouca variação ao longo do tempo. As maiores concentrações na precipitação ocorreram em função do acúmulo de aerosóis na atmosfera, após um período longo sem chuva. Aparentemente a vegetação exerceu influência mais evidente sobre o nitrato em relação aos demais nutrientes. O fluxo dos nutrientes foi variável, onde principalmente a entrada total destes deu-se em função de eventos individuais de chuva de grande magnitude. O balanço em kg.ha-1.ano-1 foi positivo para todos os nutrientes com os seguintes ganhos líquidos: Ca+2 (2,33); Mg+2 (1,66); Na+ (2,07); K+ (l,80) e NO3 (5,84).

Relevância:

30.00% 30.00%

Publicador:

Resumo:

Um estudo longitudinal clínico, radiológico e eletrocardiográfico do tipo caso-controle realizado no município de Virgem da Lapa, Minas Gerais, Brasil, com o acompanhamento de 124 chagásicos crônicos durante seis anos, revelou que 62,1% dos pacientes permaneceram com o quadro inicial inalterado, a maioria deles na forma indeterminada, 32,3% evoluíram com progressão da doença e 5,6% tiveram normalização do eletrocardiograma. Os resultados mencionados, quando comparados aos obtidos no grupo controle composto de pares não chagásicos da mesma idade e sexo, demonstraram uma progressão de 27,4% maior entre os pacientes com sorologia positiva, o que representa o excesso de risco ou componente exclusivamente chagásico na evolução da doença. Não houve diferença de progressão da doença em relação ao sexo, porém ela foi mais precoce e sete vezes mais freqüente em relação à cardiopatia do que ao megaesôfago, ambas ocorrendo na maioria das vezes em grau leve ou moderada. Em 192 chagásicos e 188 não chagásicos observados na área, no referido período, houve uma mortalidade 3,6 vezes maior entre os chagásicos, com uma letalidade pela cardiopatia de 8,9%, sem diferença entre os sexos, porém mais precoce no sexo masculino. A morte súbita foi mais freqüente do que a morte por insuficiência cardíaca. O prognóstico foi bom para os pacientes da forma indeterminada e digestiva e reservado para os casos de cardiopatia, principalmente os de graus mais elevados.